GC Biopharma sells HK subsidiary to CR Pharm Group for $254 mn

It will supply blood product Albumin and genetically recombinant hemophilia treatment GreenGene F to China's firm

GC Biopharma sells HK subsidiary to CR Pharm Group for 4 mn
Young-ae Lee 1
2024-07-18 10:24:42 0ae@hankyung.com
Bio & Pharma

South Korea’s GC Biopharma Corp. announced on Wednesday that it signed a share purchase agreement (SPA) to sell all its shares in its Hong Kong subsidiary to a subsidiary of China Resources Pharmaceutical Group.

The total sale amount is 350 billion won ($254 million).

Last year, China Resources recorded sales of $34 billion. GC Biopharma stated that this sale would enhance its financial stability and secure funds for future business investments.

GC Biopharma expects its export to the Chinese market will gain momentum through the contract with CR Pharmaceutical, which has a nationwide distribution network in China.

GC Biopharma announced that it will supply CR Pharmaceutical with the blood product Albumin and the genetically recombinant hemophilia treatment GreenGene F, both produced at its Ochang plant in North Chungcheong Province. The contract size is about 85 billion won ($61.7 million).

The company plans to maximize the efficiency of blood product production by exporting one of the by-products, immunoglobulin, to the US and albumin to China.

China Resources Pharmaceutical Group will also distribute GC Wellbeing’s hyaluronic acid fillers in China.

Write to Young-ae Lee at 0ae@hankyung.com
#GC Biopharma #China Resources Pharmaceutical Group #immunoglobulin #albumin #GC Wellbeing

GC Biopharma exports Alyglo to US

GC Biopharma exports Alyglo to US

South Korea’s major pharmaceutical company GC Biopharma Corp. announced on Monday that it shipped the initial volume of Alygro, its immunoglobulin blood product to enter the US market.  Alyglo, which received approval from the US Food and Drug Administration (FDA) in December l

GC Biopharma aims to boost Alyglo sales sixfold in the US

GC Biopharma aims to boost Alyglo sales sixfold in the US

GC Biopharma’s Alyglo production line at its Ochang plant in South Korea (Courtesy of GC Biopharma) CHEONGJU, North Chungcheong Province -- South Korea’s major pharmaceutical company GC Biopharma Corp. aims to raise the sales of Alyglo, its immunoglobulin blood product approved by t

GC Biopharma gets FDA approval for Alyglo

GC Biopharma gets FDA approval for Alyglo

South Korea’s GC Biopharma Corp. announced on Monday that it received approval from the US Food and Drug Administration (FDA) for the immunoglobulin blood product Alyglo (intravenous immunoglobulin 10%.)Alyglo is the treatment for primary humoral immunodeficiency. GC Biopharma submitte

GC Biopharma breaks ground on blood product plant in Indonesia

GC Biopharma breaks ground on blood product plant in Indonesia

South Korea’s GC Biopharma Corp. broke ground on Wednesday on Indonesia’s first blood product plant through technology transfer.Indonesian pharmaceutical companies PT Triman and PT Medquest Jaya Global held a groundbreaking ceremony for the blood product factory in Jababeka Industr

GC Biopharma wins $10 mn order for flu vaccine in Thailand

GC Biopharma wins $10 mn order for flu vaccine in Thailand

South Korea's GC Biopharma Corp. announced on Thursday that its flu vaccine GC Flu secured a $10 million order in the upcoming bid by Thailand's Government Pharmaceutical Organization (GPO) next year.Since entering the Thai flu vaccine market in 2014, this is the largest supply for GC Biopharm
(* comment hide *}